Aventis DiaPep277 Phase III Discussion Focuses On Endpoint; Picovir Dropped
Aventis/Peptor DiaPep277 will enter Phase III trials following agreement with FDA on appropriate clinical endpoints for the diabetes agent
You may also be interested in...
Viropharma expects to have data from a Phase I drug interaction study of oral contraceptives and Picovir (pleconaril) in two to four months
Organon and Sanofi-Synthelabo will launch the injectable antithrombotic Arixtra with 240 sales reps in late January
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011